Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. A phase 2, randomized, double-blind, dose-response study.

Trial Profile

The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. A phase 2, randomized, double-blind, dose-response study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2014

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 14 Jan 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 14 Jan 2009.
    • 30 Sep 2008 Actual patients number added 274 as reported by ClinicalTrials.gov.
    • 30 Sep 2008 Planned end date (1 Sep 2003) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top